A novel CRISPR-based RNA editing platform called ΨDNA has emerged, demonstrating efficient knockdown of endogenous RNA transcripts in human cell lines. Developed by researchers and reported in Genetic Engineering News, the approach repurposes Cas12 nucleases—traditionally DNA-targeting enzymes—to recognize and cleave RNA using a DNA guide scaffold.
In laboratory tests, ΨDNA achieved 70–95% knockdown of RNA transcripts. The technology relies on a DNA-based guide structure that directs Cas12 to specific RNA targets without altering genomic DNA, potentially reducing off-target editing risks common with conventional CRISPR systems.
The platform remains in preclinical development, with no timeline yet for clinical translation. The approach offers a potential alternative to existing RNA-editing tools like ADAR-based systems, which have different delivery and targeting constraints. Regulatory pathways for DNA-guided RNA editing have not been established.
If successful in animal models, ΨDNA could expand the therapeutic toolkit for diseases involving RNA dysregulation, including certain cancers and genetic disorders. The technology is at an early stage; its specificity and durability in living organisms remain unknown. No commercial or investor announcements have been made.
Experts caution that translating robust in vitro results to in vivo efficacy requires overcoming significant hurdles, such as nucleic acid delivery and immune responses. The field awaits independent validation of the platform's performance in more complex biological systems.